Volume : 13, Issue : 09, September – 2026
Title:
INVESTIGATION OF SCHIZOPHYLLUM COMMUNE EXTRACT FOR ITS HYPOLIPIDEMIC ACTIVITY INVITRO AND INVIVO MODELS
Authors :
Harsha Vardhana M G*, Suresha B S, T Balasubramanian
Abstract :
Cardiovascular diseases are major causes of morbidity and mortality worldwide and are strongly associated with abnormalities in lipid metabolism. The present study was undertaken to evaluate the hypolipidemic activity of the ethyl acetate extract of Schizophyllum commune (EAESC) in high-fat diet-induced hyperlipidemic Wistar albino rats. Thirty male Wistar rats were randomly divided into five groups of six animals each. Hyperlipidemia was induced by oral administration of vanaspati ghee and coconut oil in a 3:1 ratio at a dose of 3 mL/kg for 21 days. The treatment groups subsequently received EAESC at doses of 250 and 500 mg/kg, while atorvastatin (10 mg/kg) was used as the standard drug. At the end of the experimental period, serum lipid parameters including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and atherogenic index (AI) were evaluated. The hyperlipidemic control group showed marked increases in TC, TG, VLDL, LDL, and AI, along with a reduction in HDL-C. Treatment with EAESC produced improvements in the lipid profile, with the high dose (500 mg/kg) showing greater effects than the low dose (250 mg/kg). At the high dose, TC, TG, VLDL, LDL, and AI were reduced to 102.73 ± 3.02, 105.05 ± 9.63, 21.01 ± 1.93, 44.23 ± 2.63 mg/dL, and 1.77 ± 0.14, respectively, while HDL-C increased to 37.49 ± 2.00 mg/dL. These findings indicate that EAESC ameliorates high-fat diet-associated alterations in serum lipid parameters and demonstrates a dose-related hypolipidemic effect. The observed activity may be associated with the bioactive constituents present in S. commune.
Keywords: Schizophyllum commune, hypolipidemic activity, high-fat diet, Triglycerides, LDL,VLDL.
Cite This Article:
Please cite this article in press Harsha Vardhana M G et al., Investigation Of Schizophyllum Commune Extract For Its Hypolipidemic Activity Invitro And Invivo Models.,. Indo Am. J. P. Sci, 2026; 13(09).
REFERENCES:
1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128.
2. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990e2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197–223.
3. Leeder S, Raymond S, Greenberg H, Liu H, Esson K. A Race Against Time: The Challenge of Cardiovascular Disease in Developing Countries. New York, NY: Trustees of Columbia University, 2004.
4. Tarride JE, Lim M, DesMeules M, et al. A review of the cost of cardiovasculardisease. Can J Cardiol 2009;25:e195–202.
5. Fuster V, Voute J. MDGs: chronic diseases are not on the agenda.Lancet 2005;366:1512–4.
6. World Health Organization. Neglected global epidemics: three growing threats. In: TheWorld Health Report, 2003: Shaping the Future. Geneva,Switzerland: WHO; 2003:83–102.
7. Mishra PR, Panda PK, Apanna KC, Panigrahi S.Evaluation of acute hypolipidemic activity of different plant extracts in Triton WR-1339 induced hyperlipidemia in albino rats. Pharmacologyonline. 2011; 3:925-34.
8. Mizuno T. The extraction and development of antitumor-active polysaccharides from medicinal mushrooms in Japan. International Journal of medicinal mushrooms. 1999;1(1).
9. Chang ST. Global impact of edible and medicinal mushrooms on human welfare in the 21st century: nongreen revolution. International journal of medicinal mushrooms. 1999;1(1).
10. Wasser SP, Weis AL. Medicinal properties of substances occurring in higher basidiomycetes mushrooms: current perspectives. International Journal of medicinal mushrooms. 1999;1(1).
11. Reshetnikov SV, Tan KK. Higher Basidiomycota as a source of antitumor and immunostimulating polysaccharides. International Journal of Medicinal Mushrooms. 2001;3(4).
12. Wasser SP. Medicinal mushrooms: ancient traditions, contemporary knowledge, and scientific enquiries. International journal of medicinal mushrooms. 2007 Jan 1;9(3-4):187-368.
13. Van Griensven LJ. Culinary-medicinal mushrooms: Must action be taken?. International Journal of Medicinal Mushrooms. 2009 Jan 1;11(3):281.
14. Albina T, Kaur J, Bhadariya V. Schizophyllum commune: A promising functional ingredient for food and medicine. Journal of Food Chemistry and Nanotechnology. 2023 Oct 31;9(S1):S204-10.
15. Sun, T.-K.; Huang, W.-C.; Sun, Y.-W.; Deng, J.-S.; Chien, L.-H.; Chou, Y.-N.; Jiang, W.-P.; Lin, J.-G.; Huang, G.-J. Schizophyllum commune Reduces Expression of the SARS-CoV-2 Receptors ACE2 and TMPRSS2. Int. J. Mol. Sci. 2022, 23, 14766.
16. Munshi RP, Joshi SG, Rane BN. Development of an experimental diet model in rats to study hyperlipidemia and insulin resistance, markers for coronary heart disease. Indian Journal of Pharmacology. 2014;46(3):270.
17. Jung K. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, Carl A. Burtis, Edward R. Ashwood, and David E. Bruns, editors. St. Louis, MO: Elsevier Saunders, 2006, 2448 pp., $229.00, hardcover. ISBN 0-7216-0189-8. Clinical Chemistry. 2006 Jun 1;52(6):1214.
18. Nauck M, Graziani MS, Bruton D, Cobbaert C, Cole TG, Lefevre F, Riesen W, Bachorik PS, Rifai N. Analytical and clinical performance of a detergent-based homogeneous LDL-cholesterol assay: a multicenter evaluation. Clinical chemistry. 2000 Apr 1;46(4):506-14.
19. Dominiczak M, McNamara J. The system of Cardiovascular prevention. 103.125; Nauk M, Wiebe D, Warnick G. Measurement of High-Density-Lipoprotein Cholesterol. 221.244. handbook of lipoprotein testing (eds. Rifai, Warnick and Dominiczak),. 2000.